Talukdar Rupjyoti, Reddy D Nageshwar
Clinical Pancreatologist (Fellowship, Mayo Clinic, USA) and Clinician Scientist (Wellcome DBT Fellow), Head Pancreas Research Group, Asian Institute of Gastroenterology/Asian Healthcare Foundation, Hyderabad, Telangana.
DM Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, Telangana.
J Assoc Physicians India. 2017 Sep;65(9):64-70.
The objective of the present review is to focus on pancreatic exocrine insufficiency that is associated with Type 1 and 2 diabetes, its clinical and therapeutic implications, including the utility and efficacy of pancreatin supplementation. A literature search was conducted on Pubmed / Medline to identify relevant articles using terms pancreatic exocrine insufficiency in diabetes mellitus patients, pathophysiology, prevalence, treatment and management published between 2006-2016 in English language. Meta-analysis has revealed the prevalence of PEI in patients with type-1 and type-2 diabetes mellitus to be 37.7% (CI 27.2-49.5) and 26.2% (CI 19.4-34.3) respectively. Very scanty data are available that evaluates the efficacy of pancreatin in patients with diabetes. In the available studies, pancreatin was found to reduce hypoglycemia in insulin treated patients. Pancreatic exocrine insufficiency in type 1 and 2 diabetes mellitus is not uncommon and correct use of pancreatin may have a positive effect on the glycemic status of the diabetic patients.
本综述的目的是聚焦于与1型和2型糖尿病相关的胰腺外分泌功能不全，及其临床和治疗意义，包括胰酶补充剂的效用和疗效。在Pubmed / Medline上进行了文献检索，以使用2006年至2016年间以英文发表的糖尿病患者胰腺外分泌功能不全、病理生理学、患病率、治疗和管理等术语来识别相关文章。荟萃分析显示，1型和2型糖尿病患者中胰腺外分泌功能不全的患病率分别为37.7%（CI 27.2 - 49.5）和26.2%（CI 19.4 - 34.3）。评估胰酶对糖尿病患者疗效的数据非常少。在现有研究中，发现胰酶可降低胰岛素治疗患者的低血糖发生率。1型和2型糖尿病中的胰腺外分泌功能不全并不罕见，正确使用胰酶可能对糖尿病患者的血糖状况产生积极影响。
